Regularizing Extrapolation in Causal Inference

0:00So we rely on these incredibly powerful models. You know, stats, machine learning to figure things out, predicting stocks, understanding if a drug works. Absolutely. They're fundamental tools now. But there's this nagging problem, isn't there? This like crisis of confidence when the data you train your model on looks really different from the group you actually want to use it for. That is the absolute core of the extrapolation problem. And it crops up everywhere. Causal inference, domain adaptation, making sure clinical trial results actually mean something for the general population. Many common methods, you know, ordinary least squares, OLS, and inverse propensity score weighting, IPW, they fundamentally operate as, well, linear smoothers.

0:42They predict something by taking a weighted average of the outcomes you already saw in your training data. Okay, a weighted average. And the sources we're diving into today suggest a pretty radical rethink about how we handle the risk that comes with those weights. That's right. It's a philosophical shift, really. So our mission today is to unpack this shift. There's this new idea, the bias-bias variance trade-off. We want to show how it lets researchers move beyond these sort of binary all-or-nothing choices about assumptions. And systematically control how much they rely on those assumptions, which is crucial, absolutely crucial, for getting credible results for groups that are often, well, left out or underrepresented in the data we have.

1:23Okay, let's ground ourselves first. The basic structure, you said weighted averages. Yeah. At the heart of it, whether it's a simple linear regression or a complex random forest, many methods boil down to calculating weights for each data point in your source group. And those weights decide how much influence each source point has on the final prediction for your target group. Exactly. And historically, there's been this big divide, sort of two main camps, based on one simple question. Can the weights be negative? Ah, okay. So camp one, non-negative weights. That sounds intuitive. Like traditional IPW, maybe matching methods.

1:58Precisely. Methods that enforce a strict rule, weights must be zero or positive. The thinking here is sort of, I only trust combinations of things I've actually observed. What's the upside of sticking to positive weights? Well, it feels safer in some ways. You limit how much you depend on, say, assuming a perfectly linear relationship when reality might be curved. You know, those parametric assumptions. Reduces reliance on the model's form. Right. And it often reduces the variance of your estimate, makes it more stable. But, and this is a big but. There's always a but. There is. Especially when your source and target groups are very different, what we sometimes call poor positivity or in high dimensions.

2:39the cost is often much worse feature imbalance. Meaning the weighted source group still doesn't really look like the target group you care about. Exactly. If your target is mostly older folks, but your source is mostly younger folks, just using positive weights might mean your adjusted group of young people still doesn't match the characteristics of the older group well enough. So you avoid extrapolation risk, but you get this bias because the groups are still mismatched. Distributional imbalance. Okay. That's one kind of bias. Now, the other camp, estimators would say, sure, use negative weights.

3:12Think OLS, kernel ridge regression. OLS is kind of like saying, I trust my equation, my model's structure. How does a negative weight even work conceptually? It's clever, actually. It allows the model to mathematically synthesize a target point that might lie between or beyond your observed data. Imagine you want to predict for age 50, but you only have data at age 40 and age 60. Okay. OLS might give a positive weight to the 60-year-old and a negative weight to the 40-year-old to effectively extrapolate to push the estimate towards 50 based on the linear trend it assumes. Ah, I see. So it can potentially do a much better job matching the features, reducing that distributional imbalance bias.

3:55Yes. It often achieves much better covariate balance. That's the big advantage. But you're paying a price for that balance, I assume. You definitely are. Two big risks. First, you are heavily reliant on your model assumptions being correct. If you assumed a straight line, linearity, but the real relationship is a curve. That negative weight extrapolation could send your prediction way off into uncharted territory. Precisely. Big model misspecification bias. And second, you generally increase the variance of your estimator. The results can be more sensitive to noise. So it feels like we've always been stuck.

4:28Either you go with traditional weighting like IPW, basically no extrapolation, but you risk poor balance. Or you go with something like OLS, uncontrolled extrapolation, better balance maybe, but you're betting heavily on potentially shaky assumptions. That's the dilemma this new work tackles head on. The goal is to find a middle ground, controlled extrapolation. Okay. How do they achieve that? What's the mechanism? The key insight is to replace that hard non-negativity rule, the binary yes-no, on negative weights with a soft constraint. They introduce a new tuning parameter, a hyperparameter, called gamma or gamma.

5:02Gamma. So this is the new control knob, the dial that lets you decide how much extrapolation you're willing to tolerate. Exactly. It directly penalizes the use and magnitude of negative weights. But it's not just about adding a penalty term, it's about recognizing what you're really trying to optimize. What do you mean? Why wasn't this done before? Just add a penalty. Right. Well, it seems simple, but the conceptual leap was realizing the standard objectives were missing a piece of the puzzle when extrapolation risk is high. This framework shows you need to manage three things simultaneously, and that gives rise to the bias-bias variance tradeoff.

5:38Bias-bias variance. Okay, break that down for us. What are the three things being balanced in their optimization? Right. So component one, let's call it term A bias from distributional imbalance. This is the classic goal. Make the weighted source data look as much like the target population in terms of features as possible. Minimize the mismatch between the groups. If my target is marathon runners, make my weighted group of sprinters look more like marathon runners. Got it. Correct. Component two, term B estimator variance. This is handled by a familiar friend, the regularization parameter lambda lambda.

6:12It smooths the weights, stops any single data point from having crazy high influence. Standard regularization. Yeah. Controls instability, noise sensitivity. Okay, what's the third, the new one? Term C is the innovation, bias for model misspecification, which you can think of as extrapolation risk. This term specifically targets and penalizes those negative weights. It quantifies the bias you introduce if you try to fix the imbalance, term A, using a model that's fundamentally wrong about the underlying relationships. Ah, okay, so bias A is the group mismatch. Bias C is the risk that your mathematical fix for that mismatch is based on a faulty assumption, like linearity when it's not linear.

6:52You've got it. And our new knob, Tei, directly controls this second type of bias, the extrapolation risk bias. How does gamma work in practice then? What happens at the extremes? Okay, imagine a researcher sets gamma to zero. No penalty on negative weights at all. So anything goes. Right. The framework just becomes the standard unconstrained problem, like OLS. You're allowing full uncontrolled extrapolation. You're basically saying, I completely trust my parametric assumptions. And if you crank gamma way up, towards infinity. Then even the tiniest negative weight incurs a massive penalty. The optimization forces all weights to be non-negative to avoid it.

7:30So you end up back at the traditional hard constraint, like IPW. Minimal extrapolation. Exactly. Increasing the weightier means you're increasingly skeptical of your model assumptions. You're constraining extrapolation, reducing that model misspecification bias, bias C. But the cost is you likely worsen your distributional imbalance, bias C. That's the tradeoff made explicit. And the synthetic data they show really drives this home. They tested it first where the underlying data generating process, the DGP, was perfectly linear. The assumption holds. And in that case, unsurprisingly, the lowest estimation error, the best mean squared error, happened when gamma was basically zero.

8:07Makes sense. If your linear assumption is correct, you should extrapolate fully using OLS-like methods to get the best balance. But then they deliberately broke the assumption. They made the true underlying relationship nonlinear, adding quadratic terms interactions. So the linear model is now definitely wrong. Yes. And suddenly allowing full extrapolation, gamma near zero, led to terrible results, really high error rates, because the linear model was extrapolating way off course from the actual curved reality. In the sweet spot. The lowest error occurred at a moderate nonzero value of gamma jail.

8:43You needed some penalty on extrapolation, but not the extreme non-negativity constraint either. That perfectly illustrates the Tobias-Bias tradeoff. You have to balance the bias from group mismatch against the bias from your potentially wrong model assumptions. Precisely. It forces you to confront and manage both risks. Okay, this is fascinating theoretically, but let's make it concrete. How does this apply in the real world, maybe in medicine? The sources looked at opioid use disorder treatments, right? Yes, a really important application. They looked at generalizing findings from the START trial, which compared buprenorphine versus methadone for OUD.

9:19The goal was to apply these findings to a broader national population from the TEDxE database. And there was a specific subgroup where this extrapolation was particularly dicey. Absolutely. They focused on Latina women with a history of using both amphetamines and benzodiazepines before treatment. Why that group specifically? Because this group was found to be significantly underrepresented in the original START trial compared to their prevalence in the national TEDxA population. This wasn't just theory. It was a practical, severe violation of the positivity assumption. So you need to estimate treatment effects for this vulnerable group.

9:55But you have very little direct data on them in your main trial. Extrapolation isn't optional. It's necessary. Exactly. So they looked at what the two traditional extremes would estimate for this specific subgroup. Let's start with linear regression, OLS, full extrapolation allowed, low gamma. OLS estimated a treatment effect of negative 0.278. That's a huge effect. It suggests that for this group, the relapse rate would be almost 28 percentage points lower on methadone compared to buprenorphine. Wow, clinically that's a massive difference. But how reliable is that number, given the lack of data?

10:31Well, when you look under the hood at the mechanics, the amount of negative influence essentially, the degree of extrapolation driving that result was really high, something like 35 % to 40 % across the two treatment arms. So that big effect hinges almost entirely on believing the linear model is perfectly correct for this group that was barely in the study to begin with. Seems fragile. Very fragile. Now, contrast that with traditional IPW, the no extrapolation approach, high gamma. Right. Enforces non-negative weights. Yeah. We get condolers. It's negative influence zero by definition, and its estimated treatment effect, almost zero too, negative vol.014, basically suggesting the two treatments are equally effective for this group.

11:11So IPW avoids the extrapolation risk. But at the cost of demonstrably worse covariate balance compared to OLS, the reweighted group using IPW was a much poorer match for the target population characteristics. Okay, so for this critical subgroup, we're left with two wildly different answers from the traditional methods. Either methadone is vastly better, but based on shaky extrapolation, or there's no difference, but based on a poorly balanced comparison. Neither feels very solid. And this is precisely where the new framework shines as a sensitivity analysis tool. The researchers didn't just pick one extreme, they systematically varied both the extrapolation penalty JAMA and the variance penalty Lambda.

11:54And they plotted how the treatment effect estimate changed as they tweaked those knobs. Exactly. And the results were striking. The estimated treatment effect for this specific vulnerable subgroup smoothly shifted as they changed the regularization. How so? When gamma was very low, minimal penalty on extrapolation, the estimate landed right back at that big negative OLS number, negar 0.278. As expected. But as they gradually increased gamma, dialing up the penalty against extrapolation, the estimate steadily moved towards zero. Okay. And depending on the level of variance regularization they used, the estimate didn't just stop at zero.

12:30For some settings, it actually crossed zero and became slightly positive. Whoa. So the sign of the effect flipped, suggesting methadone might even be slightly worse under certain assumptions. Potentially, yes, for some combinations of the tuning parameters. The main point wasn't the exact number, but the instability. The fact that the conclusion changes so drastically depending on how much extrapolation you allow. Precisely. It provides this direct visual sensitivity analysis. It shows clear as day that for this underrepresented group, the estimated treatment effect is highly sensitive to your modeling choices, specifically your tolerance for extrapolation.

13:08So let's try to synthesize this. This framework isn't just another estimator. It's a way to move beyond that stark choice. Either enforce hard non-negativity or allow unconstrained estimation. It gives you a whole spectrum in between. A continuous spectrum of regularization, yeah. It gives applied folks a much more nuanced toolkit for dealing with these positivity violations, which, let's face it, happen all the time with real data. It's about transparency, then, being honest about the assumptions. I think so. It equips researchers to really stress test their findings. You know, if you find that just slightly nudging that gamma dial, slightly restricting extrapolation makes your key result for an important subgroup completely flip.

13:50Then you know that result is built on pretty shaky ground. It's fragile. Exactly. Fragile is the right word. It suggests the conclusion might be driven more by the researcher's implicit choice about modeling philosophy than by robust evidence for that specific group. Which is a critical finding in itself. Definitely. And that leads us to a final, maybe uncomfortable thought for you, the listener. The work we discuss really highlights just how incredibly sensitive these estimates can be for underrepresented groups. They depend so much on modeling assumptions when data is sparse. So given this fragility, given the inherent risks of relying on mathematical extrapolation to bridge these huge data gaps, especially for vulnerable populations, what's our responsibility?

14:35Should we be pushing harder for more representative data collection in the first place? It's a tough question. Is it truly ethical to rely so heavily on models to tell us what works for certain groups when we know the answers those models give are potentially so unstable? Maybe the ultimate solution isn't just better modeling techniques, but better, more inclusive data from the start to minimize the need for such risky extrapolation altogether. That's a powerful point to end on. If the model's assumptions are doing most of the work for a particular subgroup, perhaps the data collection itself wasn't sufficient for that group.

15:10Something to really consider when designing future studies. Absolutely. Food for thought. Thank you for walking us through this complex but really important development. My pleasure. It was a great discussion.